Table 1 Baseline characteristics
Variable | Value |
|---|---|
Gender (male), n | 130 (50%) |
Age, y | 82 ± 1.8 |
Height, cm | 166 ± 8.5 |
Weight, kg | 68 ± 12.1 |
BMI | 24.8 ± 3.6 |
Comorbidity | |
> COPD, n | 58 (22%) |
> Preoperative EF,% | 53.5 ± 10.8 |
> Preoperative EF ≤40%, n | 41 (17%) |
> Preoperative EF ≤30%, n | 14 (5.9%) |
> Peripheral vasculopathy, n | 86 (33%) |
> Hypertension, n | 146 (56%) |
> Type II Diabetes, n | 32 (12%) |
> Carotid stenosis, n | 43 (17%) |
> Chronic pulmonary disease, n | 39 (15%) |
> Angina, n | 95 (15%) |
> Previous AMI, n | 38 (15%) |
> Previous TIA or stroke, n | 115 (44%) |
> Previous vascular surgery, n | 16 (6.15%) |
> Euroscore standard | 8.3 ± 2.3 |
> Endocarditis | 5 (1.9%) |
> Chronic renal failure, n | 32 (12%) |
> Dialysis, n | 0 (0%) |
Charlson Comorbidity Index | 6 ± 1.3 |
NYHA class | |
> I, n | 15 (8.4%) |
> II, n | 82 (46%) |
> III, n | 74 (42%) |
> IV, n | 7 (4%) |
Timing of surgery | |
> Emergency, n | 5 (2%) |
> Urgency, n | 33 (13%) |
> Planned, n | 222 (85%) |
Redo, n | 11 (4.2%) |
Preoperative IABP, n | 5 (1.9%) |
Chronic Therapy | |
> Antiplatelets, n | 97 (37%) |
> Diuretics, n | 141 (54%) |
> Betablockers, n | 95 (37%) |
> Antibiotics, n | 5 (1.9%) |
> Ca-channels antagonists, n | 55 (21%) |
> Nitrates, n | 66 (25%) |
> ACE- inhibitors, n | 151 (58%) |
> Oral anticoagulants, n | 111 (14%) |
> Heparin, n | 35 (13%) |
Bilirubine, mg/dl | 0.8 ± 0.4 |
Creatinine, mg/dl | 1.06 ± 0.4 |